Caracterização de variantes patogênicas nos genes BRCA 1 e 2 e suas associações com câncer de próstata

Authors

  • Maria Eduarda Höehr Zwetsch Univates
  • Victoria Marcon Kaspary Univates
  • Caroline Dalla Lasta Frigeri Univates e Hospital Bruno Born
  • Adriane Pozzobon Univates

DOI:

https://doi.org/10.17058/rips.v4i3.16800

Keywords:

Câncer de Próstata, BRCA, Mutação

Abstract

Objetivo: verificar em bases de dados as variantes patogênicas associadas aos genes BRCA 1 e 2 e sua associação com câncer de próstata e relacionar a ocorrência de variantes patogênicas nos genes BRCA 1 e 2 com a incidência e mau prognóstico do câncer de próstata. Método: foi realizada uma revisão bibliográfica na base de dados PubMed usando os descritores em inglês e português: mutation (mutação), BRCA, prostate cancer (câncer de próstata) cruzados aleatoriamente nos últimos 10 anos. Resultados: foram encontrados 132 artigos específicos com o as palavras, destes 11 artigos preencheram os critérios de inclusão.  A partir dos dados coletados, observou-se uma associação nas variantes patogênicas do BRCA 1 e 2 com câncer de próstata (CaP). A prevalência das mutações entre BRCA1 e BRCA2 divergiu conforme os artigos, sendo mais frequentes mutações deletérias nos genes em questão. Contudo todas foram fortemente associadas ao CaP e mau prognóstico. Considerações finais: apesar de a literatura divergir entre as prevalências e tipos das mutações, devido à variações metodológicas e características da amostra, é importante a realização de pesquisas bibliográficas que avaliam o impacto das variantes patogênicas BRCA 1 e 2 no manejo do paciente com câncer de próstata, já que a presença está associada a um mau prognóstico.

Downloads

Download data is not yet available.

Author Biographies

Maria Eduarda Höehr Zwetsch, Univates

Acadêmica curso de Medicina da Univates, Lajeado, RS

Victoria Marcon Kaspary, Univates

Acadêmica do curso de Medicina da Univates, Lajeado, RS

Caroline Dalla Lasta Frigeri, Univates e Hospital Bruno Born

Médica Oncologista do Hospital Bruno Born, Lajeado, RS

Professora assistente da Univates. 

Adriane Pozzobon, Univates

Doutor em Fisiologia Humana: UFRGS. Professor Titular da Univates, Lajeado, RS

References

Caestecker, KW e Van de Walle, GR. The role of BRCA1 in DNA double-strand repair: Past and present. Experimental Cell Research, 2013,319 (5):575–587. http://dx.doi.org/10.1016/j.yexcr.2012.11.013

de Sabando AR, Lafuente EU, García-Amigot F, Sánchez AA, Garofalo LM, Moreno S, Ardanaz E, Ramos-Arroyo MA. Correction to: Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain) .BMC Cancer 2019, 19(1):1–11. https://doi.org/10.1186/s12885-019-6277-x

Gallardo-Rincón,D, Álvarez-Gómez RM, Montes-Servín E, Toledo-Leyva,A Montes-Servín,E, Michel-Tello D. ,et al. Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients. Translational Oncology, 2020,13(2):212–220.https://doi.org/10.1016/j.tranon.2019.11.003

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, ,et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine. 2016, 375(5):443–453. https://doi.org/10.1016/j.tranon.2019.11.003

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, ,et al. Integrative clinical genomics of advanced prostate cancer. Cell,2015, 161(5):1215–1228. https://doi.org/10.1016/j.cell.2015.05.001

Page EC, Bancroft EK, Brook MN, Assel M, Battat MH, Thomas S, ,et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, (6): 831–842. https://doi.org/10.1016/j.eururo.2019.08.019

Humeniuk, MS, ZhanG, T , Armstrong, AJ. Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers. Cancer, 2017, 123(18): 3441–3444. https://doi:10.1002/cncr.30806

Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: Clinical characteristics and cancer spectrum. BMC Cancer, 2018, 18(1): 1–9. https://doi:10.1186/s12885-018-4098-y

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, ,et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study. European Urology, 2014, 66(3):489–499. https://doi:10.1016/j.eururo.2014.01.003

Leão RRN, Price AJ, Hamilton RJ. Germline BRCA mutation in male carriers - Ripe for precision oncology? Prostate Cancer and Prostatic Diseases,2018,21(1):48–56 https://doi.org/10.1038/s41391-017-0018-5

Segal N, Ber Y, Benjaminov O, Tamir S, Yakimov M, Kedar I, ,et al. Imaging-based prostate cancer screening among BRCA mutation carriers—results from the first round of screening. Annals of Oncology,2020. 31(11):1545–1552 https://doi.org/10.1016/j.annonc.2020.06.025

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, ,et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. Journal of Clinical Oncology, 2013, 31(14):1748–1757. https://doi:10.1200/JCO.2012.43.1882

Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C. ,et al. Cancer Incidence in First‐ and Second‐Degree Relatives of BRCA1 and BRCA2 Mutation Carriers . The Oncologist, 2016,21(7): 869–874. . https://doi:10.1634/theoncologist.2015-0354

Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, S, et al. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol. 2018 Aug;74(2):218-225 . https://doi:10.1016/j.eururo.2018.01.035

Song WH, Kim SH, Joung JY, Park WS, Seo HK, Chung J, ,et al. Prostate cancer in a patient with a family history of BRCA mutation: A case report and literature review. Journal of Korean Medical Science,2017, 32(2): 377–381. doi: 10.3346/jkms.2017.32.2.377

Castro, E e Eeles, R. The role of BRCA1 and BRCA2 in prostate cancer. Asian Journal of Andrology, 2012, 14(3): 409–414. https://doi:10.1038/aja.2011.150

Eeles, R e Raghallaigh, HN. Men with a susceptibility to prostate cancer and the role of genetic based screening. Translational Andrology and Urology, 2018, 7(1): 61–69. https://doi:10.21037/tau.2017.12.30

Wu Y, Gao Y, Dou X, Yue JWU, Y ,et al. Metastatic castration-resistant prostate cancer with neuroendocrine transformation and BRCA 1 germ-line mutation: A case report and literature review. OncoTargets and Therapy, 2020, 13:8049–8054. https://doi:10.2147/OTT.S264347

Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M PARP inhibitors in prostate cancer—The preclinical rationale and current clinical development. Genes, 2019, 10(8): 1–19. https://doi:10.3390/genes10080565

Pilarski, R.. The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families . American Society of Clinical Oncology Educational Book, 2019, (39): 79–86. https://doi:10.1200/EDBK_238977

Published

2022-04-22

How to Cite

Höehr Zwetsch, M. E., Marcon Kaspary, V., Dalla Lasta Frigeri, C., & Pozzobon, A. (2022). Caracterização de variantes patogênicas nos genes BRCA 1 e 2 e suas associações com câncer de próstata. Revista Interdisciplinar De Promoção Da Saúde, 4(3). https://doi.org/10.17058/rips.v4i3.16800

Issue

Section

ARTIGO DE REVISÃO